Karuna Therapeutics Statistics
Share Statistics
Karuna Therapeutics has 38.2M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 38.2M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -26.97 and the forward
PE ratio is null.
Karuna Therapeutics's PEG ratio is
-0.79.
| PE Ratio | -26.97 |
| Forward PE | n/a |
| PS Ratio | 17886.71 |
| Forward PS | n/a |
| PB Ratio | 9.33 |
| P/FCF Ratio | -30.09 |
| PEG Ratio | -0.79 |
Financial Ratio HistoryEnterprise Valuation
Karuna Therapeutics has an Enterprise Value (EV) of 11.53B.
| EV / Sales | 17628.09 |
| EV / EBITDA | -23.38 |
| EV / EBIT | -29.88 |
| EV / FCF | -29.66 |
Financial Position
The company has a current ratio of 19.31,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.31 |
| Quick Ratio | 18.82 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -34.58% and Return on Invested Capital is -38.99%.
| Return on Equity | -34.58% |
| Return on Assets | -32.46% |
| Return on Invested Capital | -38.99% |
| Revenue Per Employee | $1,929.2 |
| Profits Per Employee | $-1,279,292.04 |
| Employee Count | 339 |
| Asset Turnover | 0 |
| Inventory Turnover | 0.05 |
Taxes
| Income Tax | 670K |
| Effective Tax Rate | -0.15% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.15, so Karuna Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 317.67 |
| 200-Day Moving Average | 228.83 |
| Relative Strength Index (RSI) | 75.4 |
| Average Volume (20 Days) | 971,825 |
Income Statement
In the last 12 months, Karuna Therapeutics had revenue of 654K
and earned -433.68M
in profits. Earnings per share was -11.73.
| Revenue | 654K |
| Gross Profit | -1.05M |
| Operating Income | -494.78M |
| Net Income | -433.68M |
| EBITDA | -493.08M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -11.73 |
Full Income StatementBalance Sheet
The company has 185.82M in cash and 16.69M in
debt, giving a net cash position of 169.13M.
| Cash & Cash Equivalents | 185.82M |
| Total Debt | 16.69M |
| Net Cash | 169.13M |
| Retained Earnings | -997.89M |
| Total Assets | 1.34B |
| Working Capital | 1.25B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -385.82M
and capital expenditures -2.92M, giving a free cash flow of -388.74M.
| Operating Cash Flow | -385.82M |
| Capital Expenditures | -2.92M |
| Free Cash Flow | -388.74M |
| FCF Per Share | -10.52 |
Full Cash Flow StatementMargins
Gross margin is -160.09%, with operating and profit margins of -75653.98% and -66311.93%.
| Gross Margin | -160.09% |
| Operating Margin | -75653.98% |
| Pretax Margin | -66209.48% |
| Profit Margin | -66311.93% |
| EBITDA Margin | -75393.88% |
| EBIT Margin | -75653.98% |
| FCF Margin | -59439.76% |
